NCT03746431 2026-01-07A Phase 1 Study of [225Ac]-FPI-1434 InjectionFusion Pharmaceuticals Inc.Phase 1 Terminated78 enrolled
NCT03449108 2025-11-21LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue SarcomasM.D. Anderson Cancer CenterPhase 2 Active not recruiting30 enrolled
NCT02404441 2022-08-03Phase I/II Study of PDR001 in Patients With Advanced MalignanciesNovartisPhase 1/2 Completed319 enrolled 41 charts
NCT02637531 2022-04-04A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549Infinity Pharmaceuticals, Inc.Phase 1 Unknown219 enrolled